RetinaRisk calculates a patient’s risk level and suggests a recommended screening interval using key clinical inputs

Remidio Innovative Solutions, an AI-powered ophthalmic diagnostics, has announced a strategic partnership with RetinaRisk, a health-tech company from Iceland, to enhance risk-based diabetic retinopathy (DR) screening in India and Iceland.

RetinaRisk calculates a patient’s risk level and suggests a recommended screening interval using key clinical inputs such as HbA1c, blood pressure, diabetes type and duration, and DR status.

From a public health perspective, this enables more cost-effective DR screening programmes by individualising screening intervals—extending the frequency for low-risk individuals while ensuring timely follow-up for high-risk cases.

“This collaboration moves us beyond detection into prediction, enabling care pathways that are not just reactive but truly preventative,” said Dr Anand Sivaraman, CEO, Remidio. “It aligns perfectly with our mission to eliminate preventable blindness using technology that is clinically robust, scalable, and accessible.”

Aegir Thor Steinarsson, CEO, RetinaRisk commented, “We are excited to deepen our collaboration with Remidio, whose Fundus on Phone (FOP) and Medios DR AI platform are already being used successfully in Iceland for diabetic retinopathy screening. The ability to combine our risk prediction algorithm with real-time retinal grading—delivered via a portable, smartphone-based solution—is truly game-changing. Together, we are demonstrating that AI-enabled screening can be made accessible, personalised, and impactful in both developed and emerging healthcare systems.”

The partnership will kick off with pilot programmes targeting high-prevalence diabetic populations in India, aiming to create a scalable framework for prioritised referrals, longitudinal tracking, and reduced vision loss due to DR.